AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

ASX:PIQProteomics Int Lab Stock Price, Forecast & News

A$0.36
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.35
Now: A$0.36
A$0.36
50-Day Range
A$0.27
MA: A$0.33
A$0.36
52-Week Range
A$0.20
Now: A$0.36
A$0.44
Volume126,546 shs
Average VolumeN/A
Market Capitalization$32.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; and the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment. The company was founded in 2001 and is based in Perth, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.28 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 9389 1992

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Cash FlowA$0.03 per share
Book ValueA$0.05 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$32.62 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PIQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PIQ and its competitors with MarketBeat's FREE daily newsletter.

Proteomics Int Lab (ASX:PIQ) Frequently Asked Questions

How has Proteomics Int Lab's stock been impacted by COVID-19 (Coronavirus)?

Proteomics Int Lab's stock was trading at A$0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PIQ stock has increased by 36.5% and is now trading at A$0.36. View which stocks have been most impacted by Coronavirus.

Has Proteomics Int Lab been receiving favorable news coverage?

News articles about PIQ stock have been trending very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Proteomics Int Lab earned a news impact score of -3.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutProteomics Int Lab.

Who are some of Proteomics Int Lab's key competitors?

What other stocks do shareholders of Proteomics Int Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteomics Int Lab investors own include Woolworths Group (WOW), Patrys (PAB), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

Who are Proteomics Int Lab's key executives?

Proteomics Int Lab's management team includes the following people:
  • Dr. Richard John Lipscombe M.A., Ph.D., Ph.D., (London), MA (Oxford), Co-Founder, MD & Director
  • Dr. Pearl Tan, Chief Operating Officer
  • Mr. John Chuck Morrison, Head of Bus. Devel.
  • Ms. Karen Teresa Logan B.Com., BCom, DipAppCorpGov, ACIS, FFin, AGIA, GAI, Company Sec.

What is Proteomics Int Lab's stock symbol?

Proteomics Int Lab trades on the ASX under the ticker symbol "PIQ."

What is Proteomics Int Lab's stock price today?

One share of PIQ stock can currently be purchased for approximately A$0.36.

How big of a company is Proteomics Int Lab?

Proteomics Int Lab has a market capitalization of $32.62 million and generates $2.76 million in revenue each year.

What is Proteomics Int Lab's official website?

The official website for Proteomics Int Lab is www.proteomics.com.au.

How can I contact Proteomics Int Lab?

The company can be reached via phone at 61 8 9389 1992.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.